Vinai Gondi, Bridget Koontz, Priya Rastogi, Lisa Lenrow named to NRG Oncology committee leadership

Cancer centers adapt to life without site visits as NIH changes CCSG review

Love them or hate them, site visits have been a part of the culture of NCI-designated cancer centers for decades, shaping the process for admitting members to the elite club and influencing internal politics within institutions.

Jonathan Licht named president, chief scientific officer at Van Andel Institute

Jonathan D. Licht was named president and chief scientific officer of the Van Andel Institute. Licht will begin his new role in early 2026.

October 31, 2025

Vol.51 No.40

In Brief

Eytan Ruppin named deputy director of Translational Research Institute at Cedars-Sinai

Eytan Ruppin, a data scientist who works with AI-based methods for predicting individual patients’ response to cancer therapies, has joined Cedars-Sinai Cancer as deputy director of the Translational Research Institute. He will also serve as director of Integrative Data Sciences in the Division of Surgical Research.

October 31, 2025

Vol.51 No.40

Clinical Roundup

Ozekibart improves PFS in chondrosarcoma, registrational phase II trial shows

Positive topline results from the registrational ChonDRAgon study investigating ozekibart (INBRX-109) as a single agent versus placebo in patients with advanced or metastatic, unresectable chondrosarcoma were recently reported.

October 31, 2025

Vol.51 No.40

Cancer Policy

Shutdown precluded NCI officials from appearing at AACI/CCAF annual meeting

NCI officials were notably absent from the annual meeting of the Association of American Cancer Institutes and the Cancer Center Administrators Forum in Washington, DC, due to the government shutdown that started on Oct. 1.

Zanzalintinib + atezolizumab improve survival in advanced CRC

Combining zanzalintinib, a targeted therapy drug, and atezolizumab, an immune checkpoint inhibitor, helped patients with metastatic colorectal cancer live longer and control their disease better than with the standard treatment drug regorafenib, according to a study led by UCLA investigators.

October 24, 2025

Vol.51 No.39

Vinai Gondi, Bridget Koontz, Priya Rastogi, Lisa Lenrow named to NRG Oncology committee leadership

YOU MAY BE INTERESTED IN

Cancer centers adapt to life without site visits as NIH changes CCSG review

Jonathan Licht named president, chief scientific officer at Van Andel Institute

Eytan Ruppin named deputy director of Translational Research Institute at Cedars-Sinai

Ozekibart improves PFS in chondrosarcoma, registrational phase II trial shows

Shutdown precluded NCI officials from appearing at AACI/CCAF annual meeting

Zanzalintinib + atezolizumab improve survival in advanced CRC

Renew today!

Subscriber content

Never miss an issue!

Login